<DOC>
	<DOCNO>NCT00103623</DOCNO>
	<brief_summary>Praecis currently conduct 2000 patient Experience Study ; Phase IV commitment postmarketing safety study Food Drug Administration ( FDA ) indicate population patient receive Plenaxis® . The purpose study estimate incidence immediate-onset systemic allergic reaction indicate population receive Plenaxis® determine whether hazard rate change time .</brief_summary>
	<brief_title>The Plenaxis® Experience Study</brief_title>
	<detailed_description>This postmarketing patient safety study FDA indicate population patient receive Plenaxis® . On quarterly basis , patient enrol Plenaxis® Experience Study chart audit record number immediate-onset systemic allergic reaction may occur receive Plenaxis® . The study close 2,000 patient enrol . If immediate onset allergic reaction occur , patient may eligible enroll second protocol ( skin test patient experience immediate onset allergic reaction ) . Collection immediate-onset systemic allergic reaction continue patient enrol study patient discontinues Plenaxis® reason , patient withdraws consent continue study patient lose follow-up .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abarelix</mesh_term>
	<criteria>A subject eligible participate study meet follow criterion : Male ≥ 18 year old advance symptomatic prostate cancer LHRH agonist therapy appropriate refuse surgical castration Has least one following : 1 . Risk neurological compromise due metastasis , 2 . Ureteral bladder outlet obstruction due local encroachment metastatic disease 3 . Severe bone pain skeletal metastasis persist narcotic analgesia Patients legal representative must able read , understand sign inform consent form participate trial . Female Patients , Pediatric patient , Patients know hypersensitivity component abarelix injectable suspension</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Advanced</keyword>
	<keyword>Symptomatic</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced Symptomatic Prostate Cancer</keyword>
</DOC>